![Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review - ScienceDirect Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1063458418313153-gr3.jpg)
Disease-modifying effects of COX-2 selective inhibitors and non-selective NSAIDs in osteoarthritis: a systematic review - ScienceDirect
![Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016 Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016](https://journals.sagepub.com/cms/10.1177/0300060516628704/asset/images/large/10.1177_0300060516628704-fig2.jpeg)
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
![Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet](https://www.thelancet.com/cms/attachment/2000989387/2003643106/gr1.jpg)
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison - The Lancet
![Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cbf40210606e2a1de2e6ed64d6621eb468e1db48/5-Table3-1.png)
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar
![PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients](https://www.researchgate.net/publication/298424480/figure/fig1/AS:341697683836945@1458478484950/Change-from-baseline-in-Global-Pain-Intensity-at-Week-12-in-Norwegian-patients-with_Q320.jpg)
PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients
![Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2002/nejm_2002.347.issue-26/nejmoa021907/production/images/img_medium/nejmoa021907_t2.jpeg)
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
![PDF) Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: A protocol for systematic review and meta analysis PDF) Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: A protocol for systematic review and meta analysis](https://www.researchgate.net/publication/340572126/figure/fig1/AS:903486816411648@1592419451532/Flow-diagram-of-study-selection_Q320.jpg)
PDF) Celecoxib vs diclofenac sodium in patients with knee osteoarthritis: A protocol for systematic review and meta analysis
![Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2002/nejm_2002.347.issue-26/nejmoa021907/production/images/img_medium/nejmoa021907_t4.jpeg)
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
![JCM | Free Full-Text | Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials JCM | Free Full-Text | Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials](https://pub.mdpi-res.com/jcm/jcm-12-03497/article_deploy/html/images/jcm-12-03497-ag.png?1684233642)
JCM | Free Full-Text | Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
![Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002934305009137-gr2.jpg)
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect
![Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016 Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016](https://journals.sagepub.com/cms/10.1177/0300060516628704/asset/images/large/10.1177_0300060516628704-fig1.jpeg)
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
![Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/63c765d9-c539-4d2f-8fde-eb1a58bf13e8/joim13505-gra-0001-m.jpg)
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
![Pharmaceutics | Free Full-Text | Anti-Psoriasis Effect of Diclofenac and Celecoxib Using the Tail Model for Psoriasis Pharmaceutics | Free Full-Text | Anti-Psoriasis Effect of Diclofenac and Celecoxib Using the Tail Model for Psoriasis](https://www.mdpi.com/pharmaceutics/pharmaceutics-14-00885/article_deploy/html/images/pharmaceutics-14-00885-g004.png)